MARKET

HROW

HROW

Harrow Health Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.49
-0.35
-3.56%
After Hours: 9.49 0 0.00% 16:00 09/24 EDT
OPEN
10.01
PREV CLOSE
9.84
HIGH
10.15
LOW
9.49
VOLUME
67.79K
TURNOVER
--
52 WEEK HIGH
11.24
52 WEEK LOW
4.650
MARKET CAP
255.22M
P/E (TTM)
36.40
1D
5D
1M
3M
1Y
5Y
--Aegis Capital Starts Harrow Health at Buy with $15 Price Target
MT Newswires · 2d ago
Looking Into Harrow Health's Return On Capital Employed
According to Benzinga Pro, during Q2, Harrow Health (NASDAQ:HROW) earned $4.17 million, a 72.13% increase from the preceding quarter. Harrow Health also posted a total of $18.13 million in sales, a 17.43% increase since Q1.
Benzinga · 4d ago
BRIEF-Harrow Health Files For Mixed Shelf Of Up To $125 Million
reuters.com · 09/03 21:16
BRIEF-Harrow Health Provides $13.5 Mln Senior Secured Loan To Melt Pharmaceuticals
reuters.com · 09/02 12:10
Harrow Health Reports Provides $13.5M Senior Secured Loan To Melt Pharma
Melt Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021 NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic-focused healthcare company, and Melt
Benzinga · 09/02 12:07
Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals
NASHVILLE, Tenn., September 02, 2021--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, toda...
Business Wire · 09/02 12:00
BRIEF-Harrow Health Inc Says Board Appointed Mark Baum, CEO, To Serve As Chairman Of Board
reuters.com · 08/23 20:36
Harrow Health Effective August 19, Board Appointed Mark L. Baum, CEO, To Serve As Chairman Of Board
-Reuters
Reuters · 08/23 20:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HROW. Analyze the recent business situations of Harrow Health Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HROW stock price target is 15.08 with a high estimate of 15.25 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 110
Institutional Holdings: 14.20M
% Owned: 52.81%
Shares Outstanding: 26.89M
TypeInstitutionsShares
Increased
29
1.49M
New
20
705.66K
Decreased
24
2.71M
Sold Out
23
944.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Robert Kammer
Chief Executive Officer/Director
Mark Baum
Chief Financial Officer/Secretary
Andrew Boll
Corporate Executive
John Saharek
Other
Larry Dillaha
Director
Richard Lindstrom
Independent Director
Teresa Sparks
Independent Director
R. Lawrence Van Horn
No Data
  • All
  • Financials
  • Insiders
More
About HROW
Harrow Health, Inc owns a portfolio of healthcare and ophthalmology pharmaceutical business, including ImprimisRx, an ophthalmology outsourcing facility and pharmaceutical compounding business. The Company holds interest in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The Company also owns royalty rights in four clinical stage drug candidates, which is being developed by Surface Ophthalmics and Melt Pharmaceuticals.

Webull offers kinds of Harrow Health Inc stock information, including NASDAQ:HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.